It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bitter taste receptors (TAS2Rs), a subfamily of G-protein coupled receptors (GPCRs) expressed orally and extraorally, elicit signaling in response to a large set of tastants. Among 25 functional TAS2Rs encoded in the human genome, TAS2R14 is the most promiscuous, and responds to hundreds of chemically diverse ligands. Here we present the cryo–electron microscopy (cryo-EM) structure of the human TAS2R14 in complex with its signaling partner gustducin, and bound to flufenamic acid (FFA), a clinically approved nonsteroidal anti-inflammatory drug. The structure reveals an unusual binding mode, where two copies of FFA are bound at distinct pockets: one at the canonical receptor site within the trans-membrane bundle, and the other in the intracellular facet, bridging the receptor with gustducin. Together with a pocket-specific BRET-based ligand binding assay, these results illuminate bitter taste signaling and provide tools for a site-targeted compound design.
Bitter taste receptors (TAS2Rs) are a subfamily of G-protein coupled receptors (GPCRs). Here, the authors report a cryo-EM structure of the human TAS2R14 in complex with its signaling partner gustducin, and bound to an anti-inflammatory drug flufenamic acid (FFA).
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 The Hebrew University of Jerusalem, The Institute of Biochemistry, Food Science and Nutrition, Robert H. Smith Faculty of Agriculture, Food and Environment, Rehovot, Israel (GRID:grid.9619.7) (ISNI:0000 0004 1937 0538); The Hebrew University, The Fritz Haber Research Center, and the Harvey M. Kruger Center for Nanoscience & Nanotechnology, Institute of Chemistry, Jerusalem, Israel (GRID:grid.9619.7) (ISNI:0000 0004 1937 0538)
2 Weizmann Institute of Science, Department of Chemical and Structural Biology, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
3 Charterhouse Square, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary, University of London, London, UK (GRID:grid.4464.2) (ISNI:0000 0001 2161 2573)
4 The Hebrew University of Jerusalem, The Institute of Biochemistry, Food Science and Nutrition, Robert H. Smith Faculty of Agriculture, Food and Environment, Rehovot, Israel (GRID:grid.9619.7) (ISNI:0000 0004 1937 0538); The Hebrew University, The Fritz Haber Research Center, and the Harvey M. Kruger Center for Nanoscience & Nanotechnology, Institute of Chemistry, Jerusalem, Israel (GRID:grid.9619.7) (ISNI:0000 0004 1937 0538); Bar-Ilan University, Department of Chemistry, Ramat-Gan, Israel (GRID:grid.22098.31) (ISNI:0000 0004 1937 0503)
5 Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Chemistry and Pharmacy, Medicinal Chemistry, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311)
6 Weizmann Institute of Science, Structural Proteomics Unit (SPU), Life Sciences Core Facilities (LSCF), Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
7 Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Chemistry and Pharmacy, Medicinal Chemistry, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311); Friedrich-Alexander-Universität Erlangen-Nürnberg, FAUNeW – Research Center New Bioactive Compounds, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311)
8 Charterhouse Square, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary, University of London, London, UK (GRID:grid.4464.2) (ISNI:0000 0001 2161 2573); University of Liverpool, Department of Pharmacology and Therapeutics, Faculty of Health and Life Sciences, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)